Iqvia Hldgs Inc - IQV STOCK NEWS

IQVIA reported strong financial results for Q2 2021, with revenues of $3,438 million, a 36.4% increase year-over-year. Technology & Analytics Solutions revenue was $1,353 million, while Research & Development Solutions grew to $1,891 million, a 53.1% increase. The company's backlog rose to $23.9 billion, with an expected conversion of $6.6 billion into revenue. GAAP net income reached $175 million, compared to a loss last year. IQVIA raised its full-year guidance, estimating revenues of $13,550 - $13,700 million and adjusted diluted EPS of $8.70 - $8.90.

The IQVIA Institute for Human Data Science released a report titled Digital Health Trends 2021, highlighting the growing role of digital health tools in mainstream medicine. In 2020, over 90,000 new health apps emerged, totaling 350,000 available to consumers, with disease management apps rising to 47% of usage. The report emphasizes the increasing effectiveness of these tools, validated wearables, and the substantial body of evidence supporting digital health's inclusion in treatment guidelines. Key developments include expanded commercialization pathways and the incorporation of digital therapeutics and biomarkers in clinical trials.

IQVIA Holdings Inc. (NYSE:IQV) is set to announce its Q2 2021 financial results on July 27, 2021, before market open. A conference call will follow at 9:00 a.m. Eastern Time. Investors can access the earnings release and financial details on their Investor Relations website. Registration for the call is required in advance to obtain connection details. A replay will be available post-event. IQVIA is a leader in analytics and technology solutions for the life sciences, with over 72,000 employees operating in more than 100 countries.

IQVIA has launched the Clinical Data Analytics Suite (CDAS), a SaaS-based platform that integrates clinical trial data, enabling better access and predictive analytics. This solution aims to address the challenges posed by decentralized trials by allowing stakeholders to manage both structured and unstructured data efficiently. CDAS enhances decision-making in trial design and resource allocation, ultimately improving patient safety and accelerating drug development. Core components of CDAS are now available, demonstrating IQVIA's commitment to leveraging AI and machine learning in clinical research.

Q2 Solutions, a subsidiary of IQVIA, has announced a significant expansion at its Alba Campus in Livingston, Scotland. This development includes enhancing laboratory capabilities in areas such as genomics and flow cytometry, supporting growth in biopharma and pharma sectors. The expansion, supported by a multi-million-pound grant from Scottish Enterprise, aims to produce better patient outcomes and creates over 150 new jobs. Key advancements include next-generation genetic sequencing, advanced flow cytometry technologies, and a clean room dedicated to PBMC isolation.

Q2 Solutions, a subsidiary of IQVIA, has partnered with Tasso Inc. to develop diagnostic tests for decentralized clinical trials. Utilizing Tasso's patient-friendly blood collection devices, the collaboration addresses the increased demand for remote clinical trials during the COVID-19 pandemic. A pilot study validated Tasso's method against traditional blood draws, showing effective capillary blood volume retrieval. This partnership aims to enhance patient participation in clinical trials and improve diagnostic testing accessibility.

The IQVIA Institute's Global Oncology Report highlights a significant impact of COVID-19 on cancer care, with oncologists reporting 26% to 51% fewer cases than pre-pandemic levels. Despite these challenges, the oncology sector saw 3,500 new drugs in development, reflecting a 75% increase since 2015. In 2020, 17 innovative cancer drugs were launched globally, and oncology spending reached $164 billion, projected to rise to $269 billion by 2025. The report emphasizes the ongoing commitment of the global oncology community to enhance patient care despite the ongoing pandemic challenges.

IQVIA Holdings (NYSE:IQV) announced that CFO Ron Bruehlman will participate in a virtual fireside chat at the William Blair Growth Stock Conference on June 2, 2021, at 10:20 a.m. EDT. Investors can access the live audio webcast on the IQVIA Investor Relations website, with a replay available later that day. IQVIA is a global leader in analytics and clinical research, employing around 72,000 people across over 100 countries. The company focuses on enhancing patient privacy while delivering insights to improve healthcare outcomes through its innovative solutions.

The IQVIA Institute for Human Data Science released a report highlighting resilience in R&D activity despite COVID-19 disruptions in 2020. The report notes a 43% growth in the late-stage oncology drug pipeline since 2015, alongside a record 66 new drug approvals. Clinical trial productivity slightly increased but remains low due to trial complexity. R&D funding remained strong, unaffected by the pandemic, indicating robust strategic investments across the industry.